Ensysce Biosciences Receives Positive FDA Feedback on PF614-MPAR for Opioid Safety
Ensysce Biosciences has received encouraging feedback and regulatory guidance from the U.S. Food and Drug Administration (FDA) regarding its novel pain relief product, PF614-MPAR.
PF614-MPAR is an opioid analgesic developed using Ensysce’s proprietary TAAP™ (Trypsin-Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance) technologies.
These technologies aim to maintain effective pain relief while automatically triggering overdose protection if doses exceed prescribed limits, whether taken accidentally or deliberately.
The product has already been granted Breakthrough Therapy designation by the FDA, highlighting its potential to address serious unmet medical needs.
A recent FDA meeting, held on 23 July 2025, outlined the clinical and non-clinical path toward potential approval, with a focus on securing official recognition of its overdose protection capabilities.
The agency and Ensysce agreed on a collaborative framework, which includes the development of a whitepaper to support the case for overdose protection labelling.
The FDA also addressed various regulatory, manufacturing, and clinical development queries submitted by the company, and confirmed that PF614-MPAR may qualify for the expedited 505(b)(2) approval process. This could reduce the time required to bring the product to market.
Ensysce plans to apply its overdose-prevention technology beyond pain relief, with potential uses in opioid use disorder and ADHD treatments, aiming to set a new standard in drug safety.
